mRECIST v.1

Modified Response Evaluation Criteria in Solid Tumors (mRECIST) measures treatment response, specifically to cytotoxic drugs, based on tumor shrinkage.

Emma Malm

emma.snygg@hotmail.com

Cambio CDS

To measure the treatment response based on the tumor size variations in comparison to the baseline tumor size.

Use to measure the treatment response based on tumor shrinkage for patients with hepatocellular carcinoma (HCC) who have undergone treatment. The mRECIST is achieved by using the tumor size at baseline and tumor current size for 1 to 5 repeated measurements. Interpretation: -Complete response: Disappearance of any intratumoral arterial enhancement in all target lesions. -Partial response:  At least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions. -Stable disease: Any cases that do not qualify for either partial response or progressive disease. -Progressive disease - An increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started (assumed to be the sum of tumor size at baseline).

1. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13. PMID: 18477802. 2. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. doi: 10.1093/jnci/92.3.205. PMID: 10655437.

OBSERVATION.mrecist.v0, EVALUATION.mrecist_assesment.v0